Home
Storia in 1 fonti
LifeSci Capital Remains a Buy on Definium Therapeutics (DFTX)
In a report released today, Francois Brisebois from LifeSci Capital maintained a Buy rating on Definium Therapeutics, with a price target of $38...
Raccontata da
markets.businessinsider.com
- ·
LifeSci Capital Remains a Buy on Definium Therapeutics (DFTX)
In a report released today, Francois Brisebois from LifeSci Capital maintained a Buy rating on Definium Therapeutics, with a price target of $38...
- ·
Dyne Therapeutics (DYN) Gets a Buy from LifeSci Capital
LifeSci Capital analyst Francois Brisebois maintained a Buy rating on Dyne Therapeutics today and set a price target of $44.00.Claim 55% Off Tip...
- ·
LifeSci Capital Sticks to Its Buy Rating for Opus Genetics (IRD)
In a report released today, Francois Brisebois from LifeSci Capital maintained a Buy rating on Opus Genetics, with a price target of $10.00.Clai...